97 related articles for article (PubMed ID: 9222047)
1. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.
Ives KJ; Jacobsen H; Galpin SA; Garaev MM; Dorrell L; Mous J; Bragman K; Weber JN
J Antimicrob Chemother; 1997 Jun; 39(6):771-9. PubMed ID: 9222047
[TBL] [Abstract][Full Text] [Related]
2. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.
Jacobsen H; Hänggi M; Ott M; Duncan IB; Owen S; Andreoni M; Vella S; Mous J
J Infect Dis; 1996 Jun; 173(6):1379-87. PubMed ID: 8648209
[TBL] [Abstract][Full Text] [Related]
3. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
[TBL] [Abstract][Full Text] [Related]
4. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.
Jacobsen H; Haenggi M; Ott M; Duncan IB; Andreoni M; Vella S; Mous J
Antiviral Res; 1996 Jan; 29(1):95-7. PubMed ID: 8721556
[TBL] [Abstract][Full Text] [Related]
5. Rational approaches to resistance: using saquinavir.
Boucher C
AIDS; 1996 Nov; 10 Suppl 1():S15-9. PubMed ID: 8970671
[TBL] [Abstract][Full Text] [Related]
6. Saquinavir. Clinical pharmacology and efficacy.
Vella S; Floridia M
Clin Pharmacokinet; 1998 Mar; 34(3):189-201. PubMed ID: 9533981
[TBL] [Abstract][Full Text] [Related]
7. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
9. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.
Mammano F; Petit C; Clavel F
J Virol; 1998 Sep; 72(9):7632-7. PubMed ID: 9696866
[TBL] [Abstract][Full Text] [Related]
10. Saquinavir in the management of HIV infection.
Moyle G
Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
[TBL] [Abstract][Full Text] [Related]
11. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
12. Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir.
Schapiro JM; Winters MA; Vierra M; Crawford S; Merigan TC
J Infect Dis; 1998 Feb; 177(2):477-80. PubMed ID: 9466542
[TBL] [Abstract][Full Text] [Related]
13. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.
Noble S; Faulds D
Drugs; 1996 Jul; 52(1):93-112. PubMed ID: 8799687
[TBL] [Abstract][Full Text] [Related]
14. HIV therapy advances. Update on a proteinase inhibitor.
Vella S
AIDS; 1994 Sep; 8 Suppl 3():S25-9. PubMed ID: 7840913
[TBL] [Abstract][Full Text] [Related]
15. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
17. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.
Roberts NA; Craig JC; Sheldon J
AIDS; 1998 Mar; 12(5):453-60. PubMed ID: 9543442
[No Abstract] [Full Text] [Related]
18. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
20. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.
Eberle J; Bechowsky B; Rose D; Hauser U; von der Helm K; Gürtler L; Nitschko H
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):671-6. PubMed ID: 7576926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
